Trial · NCT03289650
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | 2.03 | Standard Error 1.71 | mL/min/1.73m^2 | |
| Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | -2.19 | Standard Error 1.77 | mL/min/1.73m^2 | |
| Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Acute rejection at 3 months | 0 | Participants | |
| Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus® XR (LCP-Tacro/Envarsus XR) | Acute rejection at 3 months | 1 | Participants | |
| Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Acute rejection at 12 months | 0 | Participants | |
| Number of Participants With Acute Rejection at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus® XR (LCP-Tacro/Envarsus XR) | Acute rejection at 12 months | 2 | Participants | |
| Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Graft Loss at 3 months | 0 | Participants | |
| Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | Graft Loss at 3 months | 0 | Participants | |
| Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Graft loss at 12 months | 0 | Participants | |
| Number of Participants With Graft Loss at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | Graft loss at 12 months | 0 | Participants | |
| Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Subject Death at 3 months | 0 | Participants | |
| Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus® XR (LCP-Tacro/Envarsus XR) | Subject Death at 3 months | 0 | Participants | |
| Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Subject Death at 12 months | 0 | Participants | |
| Number of Subjects Deceased at at 3 Months and 12 Months Post-Transplant | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus® XR (LCP-Tacro/Envarsus XR) | Subject Death at 12 months | 0 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Acute tubular necrosis > moderate >=2 | 2 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | Acute tubular necrosis > moderate >=2 | 2 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | Arteriolar Hyalinosis >= grade 2 | 2 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | Arteriolar Hyalinosis >= grade 2 | 2 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 1: Control Arm: Standard of Care (SOC) Tacrolimus | isometric vacuolization of tubules | 0 | Participants | |
| Number of Participants With Change in Allograft Immunohistopathology Profile | Group 2: Interventional Arm: Study Related Drug: LCP-Tacrolimus/Envarsus XR (LCP-Tacro/Envarsus XR) | isometric vacuolization of tubules | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03289650/results